[Form 4] Aptevo Therapeutics Inc Insider Trading Activity

Rhea-AI Filing Summary

USCB Financial Holdings, Inc. (Nasdaq: USCB) furnished an 8-K under Item 7.01 to announce its regular quarterly dividend.

• Amount: $0.10 per share of Class A common stock.
• Record date: August 15, 2025.
• Payment date: September 5, 2025.
• Exhibit 99.1: Press release containing the same information.
• The disclosure is treated as “furnished,” not “filed,” and carries no Exchange Act liability.

No financial statements, earnings data, or other material events were included.

Positive

• $0.10 quarterly cash dividend declared, delivering immediate shareholder return and implying management confidence in liquidity.

Negative

• None.

Insights

Equity Research Analyst

TL;DR: $0.10 cash dividend affirms capital return strategy; mildly positive for valuation.

The filing confirms a $0.10 quarterly payout, payable 5 Sep 2025 to holders of record 15 Aug 2025. Regular dividends typically support community-bank valuation multiples by offering predictable income and signaling balance-sheet strength. Because the 8-K omits payout ratio or earnings data, sustainability can’t be judged here, but continuation of distributions is incrementally favorable. The filing is narrow in scope with no operational, credit-quality, or guidance updates, limiting overall market impact.

Income Portfolio Manager

TL;DR: Sets ex-dividend timeline; useful for cash-flow planning but otherwise routine.

The announcement locks in a $0.10 dividend and key dates, allowing managers to schedule income and rebalance around the ex-dividend period. Annualized, the payment equates to $0.40, yet yield can’t be calculated without share-price data. Absence of adverse qualifiers suggests steady liquidity; still, no forward guidance accompanies the notice. Consequently, while positive for income investors, the event is not materially transformative.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Taylor Daphne

(Last) (First) (Middle)

2401 4TH AVENUE

SUITE 1050

(Street)

SEATTLE WA 98121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Aptevo Therapeutics Inc. [ APVO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, CFO

3. Date of Earliest Transaction (Month/Day/Year)
07/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/17/2025		M		3	A	(1)	3	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	07/17/2025		M			3	(2)	(2)	Common Stock	11	$0	8	D

Explanation of Responses:

1. Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.

2. On July 17, 2024, the reporting person was granted 8,550 (11 post-splits) RSUs, vesting in three approximately equal annual installments beginning on July 17, 2025.

	/s/ SoYoung Kwon, Attorney-In-Fact	07/21/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What dividend did USCB Financial Holdings (USCB) declare?

The Board declared a $0.10 per-share cash dividend on Class A common stock.

When is the USCB dividend record date?

Shareholders must own shares by August 15, 2025 to receive the dividend.

When will USCB pay the dividend?

The dividend is payable on September 5, 2025.

Is the 8-K filing considered 'filed' or 'furnished'?

It is furnished under Item 7.01 and is not subject to Section 18 liability.

Were any financial statements included in this 8-K?

No. The filing contains no financial statements or additional exhibits beyond the press release (Exhibit 99.1).